Ticker: IOVA — a small biotech company with the first FDA-approved cell therapy for a solid tumor.
Iovance makes a cancer treatment that uses a patient's own immune cells, taken from their tumor, grown into an army in the lab, and put back in the body to fight the cancer. Their first product, Amtagvi, was approved by the FDA in 2024 for advanced melanoma (skin cancer) that other treatments haven't worked on — the first therapy of its kind ever approved for a solid tumor.
Every fact below is pulled live from SEC filings, FDA records, and institutional ownership data — not summarized from memory.
Most cancer drugs are pills or IV infusions made in a factory. Iovance's approach, called TIL therapy, is different: doctors take a small piece of a patient's own tumor, pull out the immune cells already inside it that were trying (and failing) to fight the cancer, multiply them into the billions in a lab over about three weeks, and infuse them back into that same patient. It's a one-time treatment built from the patient's own body.
Amtagvi is approved today for melanoma patients who've already tried other treatments without success. Behind it, the company has eleven more programs in its pipeline SEC pipeline snapshot · 2026-02-24 — most importantly, larger studies testing whether the same approach works earlier in treatment, and in an entirely different cancer.
Not just marketing — here's what's actually scheduled or in motion, pulled from the company's own regulatory and trial disclosures.
Iovance had to resubmit its UK application with updated information; the regulator (MHRA) agreed to an expedited re-review. A decision is expected within the next few months — the most immediate approval catalyst on the board.
Highly predictable reporting pattern — this company has reported on-schedule for 46 straight quarters. Watch for Amtagvi sales growth and an updated read on cash runway.
Early results already look strong — about 1 in 4 patients responded, and among responders the benefit was still holding after two years of follow-up. If enrollment finishes on schedule, Iovance plans to file for FDA approval in lung cancer next.
Management's own target for a second approved cancer type — which would meaningfully expand how many patients this treatment can reach, well beyond melanoma.
A large study (75+ hospital sites) testing whether the treatment works as a first option for melanoma, not just a last resort. If it succeeds, it roughly doubles the number of patients who'd qualify. No results expected imminently — this one's a 2027+ story.
Iovance is still finalizing its regulatory strategy with European regulators — real, but earlier-stage than the UK decision and without a firm timeline yet.
IOVA closed most recently at $4.04. Over the past year it's roughly doubled, though it's had a bumpy ride along the way — over the last 52 weeks it's traded between about $1.70 and $5.63. Today's price sits toward the upper half of that range. The Australia approval on June 3 alone moved the stock about 16% in a single day — a real example of how these regulatory events, not hype, are what actually drive it.
Yes and no. Sales of Amtagvi are real and growing fast: the company brought in $71 million last quarter, up 45% from a year earlier 10-Q · filed 2026-05-07. But Iovance is still spending more than it earns — mostly on the large studies above — so it lost about $79 million last quarter overall.
At its current pace of spending, Iovance has roughly a year to a year and a half of cash left before it would need to raise more money or shrink its spending. This is normal for a growing biotech with a hot new drug, but it does mean there's a real chance the company issues more stock down the road to fund itself — which would modestly dilute existing shareholders.
Line-by-line differences between the 2026 and 2025 annual reports surface things a press release wouldn't headline.
In August 2025, Iovance reduced its workforce by about 19% as part of a restructuring aimed squarely at extending its cash runway 10-K · Aug 2025 restructuring, filed 2026-02-24. That's exactly the kind of move a company makes when it's taking its own cash-runway math seriously — worth knowing before assuming the "watch" item above is unaddressed.
As of January 2026, Iovance ended its manufacturing relationship with an outside contractor (Minaris) and consolidated production of Amtagvi into its own facility 10-K · filed 2026-02-24. More control over their own supply chain — and it lines up with "supplier concentration" quietly dropping off their own list of risk factors this year.
The largest professional investor is MHR Fund Management 13F · Q1 2026, filed 2026-03-31, a healthcare-focused fund holding just under 29 million shares, worth about $102 million, unchanged from the prior quarter. Three other firms opened brand-new positions in the most recent reporting period — a mild vote of confidence, though none large enough to be decisive on their own.
Clean. Iovance has never received an FDA warning letter. Its manufacturing site's most recent FDA inspection FDA inspections · FEI 3027190753, 2023 came back "No Action Indicated" — the best rating the FDA gives, meaning inspectors found nothing worth flagging.
This wasn't generated from general knowledge — it's assembled live from a set of purpose-built research tools we've been building over the past year, each one reading a different primary-source system directly: